NEW YORK, May  20, 2025  (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of the approaching May 27, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE:ATNM) securities during the period from October 31, 2022, through August 2, 2024 (“the Class Period”).

[LEARN MORE ABOUT THE CLASS ACTION]

On August 5, 2024, Actinium issued a press release providing, among other things, a regulatory update on the planned Biologics License Application (“BLA”) filing and the future plans for lomab-B, its lead product candidate, in the U.S. The press release revealed that the Company had concluded both its clinical and Chemistry, Manufacturing and Controls interaction with the FDA regarding the lomab-B BLA. Additionally, the press release noted that the FDA had determined that the analysis for the Company’s Sierra trial did not adequately support a BLA filing for lomab-B and requires an additional clinical study and the Company would need to conduct an additional clinical trial to further support the BLA filing. On this news, the price of Actinium shares declined by $3.69 per share, or approximately 59%, from $6.17 per share on August 2, 2024, to close at $2.48 on August 5, 2025.

The complaint alleges that defendants, throughout the Class Period, misled the market to believe the data submitted in support of its BLA was likely to satisfy the U.S. Food and Drug Administration’s guidelines for acceptance and approval of Actinium BLA’s.

If you purchased or otherwise acquired Actinium securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
[email protected]